First-pass extracted concept

patient-specific induced pluripotent stem cell-derived cardiomyocytes

Candidate: toolkit itemType: construct pattern1 source documents4 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

iPSC-CMs, patient-specific iPSC-CMs

Extracted Explainers

What the tool is doing

Patient-specific iPSC-CMs are used as in vitro cardiomyocyte models that retain the donor's genetic background and electrophysiological features relevant to arrhythmias. The review presents them as a central platform for modeling inherited channelopathies and related arrhythmia syndromes.

Source 1DOI PubMed

Resources required

This approach requires induced pluripotent stem cells, differentiation into cardiomyocytes, and electrophysiology-oriented phenotyping workflows. Patient-specific sourcing and culture quality are implicit prerequisites.

Source 1DOI PubMed

What problem it solves

It addresses the mismatch between traditional animal or heterologous systems and human cardiac electrophysiology. It also enables patient-specific investigation of incomplete penetrance and variable expressivity.

Source 1DOI PubMed

What it does not solve

The review states that iPSC-CM models remain limited by iPSC variation, immaturity-related in vitro limitations, and possible toxicity from gene editing. These issues can reduce fidelity or complicate interpretation.

Source 1DOI PubMed

Alternatives

The abstract contrasts iPSC-CMs with animal models and heterologous cell cultures, which are described as not truly reflecting human cardiac electro-pathophysiology.

Source 1DOI PubMed

Evidence Snippets

Patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) inherit the genetic background of the patient and reflect the electrophysiological characteristics of the native cardiomyocytes. Thus, iPSC-CMs provide an innovative and translational pivotal platform in cardiac disease modeling and therapeutic screening.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1review2024Frontiers in PhysiologyDOI PubMed

1 evidence snippet 4 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1comparative platform assessmentsupports2024Source 1DOI PubMed

Traditional animal models and heterologous cell cultures do not truly reflect human cardiac electro-pathophysiology, motivating patient-specific iPSC-CM disease models.

Claim 2platform capabilitysupports2024Source 1DOI PubMed

Patient-specific iPSC-CMs inherit patient genetic background and reflect electrophysiological characteristics of native cardiomyocytes, making them useful for cardiac disease modeling and therapeutic screening.

Claim 3platform limitationsupports2024Source 1DOI PubMed

Use of human iPSC-CMs for in vitro arrhythmia modeling is limited by variation in iPSCs and by toxicity due to gene editing on iPSCs or iPSC-CMs.

Claim 4workflow synthesissupports2024Source 1DOI PubMed

A synergistic combination of iPSCs, gene editing, 3D culture models, and all-optical platforms is proposed as a high-throughput template to recapitulate in vitro arrhythmogenic events for personalized monitoring and drug screening.